CORCEPT THERAPEUTICS INC Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
CORCEPT THERAPEUTICS INC (CORT) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $239.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $239.00K.
- CORCEPT THERAPEUTICS INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CORCEPT THERAPEUTICS INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $750.00K.
- CORCEPT THERAPEUTICS INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $239.00K 10-K · filed 2026-02-24 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-24 |
| 2023-12-31 | $750.00K 10-K · filed 2026-02-24 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |